Unlocking the Potential of F2RL1: A novel Drug Target and Biomarker for Coagulation Factor II Receptor-Like 1

Target Name: F2RL1

NCBI ID: G2150

F2RL1

Unlocking the Potential of F2RL1: A novel Drug Target and Biomarker for Coagulation Factor II Receptor-Like 1

Coagulation factor II receptor-like 1 (F2RL1) is a protein that plays a critical role in the regulation of blood clotting and hemostasis, which is vital for maintaining cardiovascular health and preventing excessive bleeding. F2RL1 is a member of the F2RL family, which is known for its role in the regulation of clotting and bleeding processes. The F2RL1 gene has been well studied, and several studies have identified its potential as a drug target or biomarker. In this article, we will explore the potential of F2RL1 as a drug target and biomarker, with a focus on its role in coagulation and its potential as a therapeutic target.

F2RL1 as a Drug Target

F2RL1 is a potential drug target due to its role in the regulation of coagulation factor II, which is a critical factor in the blood clotting cascade. The clotting cascade is a complex process that involves several proteins, including F2RL1. F2RL1 plays a critical role in the regulation of the activity of FIX, which is an essential protein in the clotting cascade.

Studies have shown that F2RL1 is a potent inhibitor of FIX activity, which means that it can prevent blood clots from forming. This has led to the possibility of F2RL1 as a drug target for thrombosis, a leading cause of cardiovascular disease. In fact, several studies have shown that inhibition of F2RL1 has been shown to be effective in treating thrombosis in both animals and humans.

F2RL1 as a Biomarker

F2RL1 has also been identified as a potential biomarker for several cardiovascular diseases, including heart failure, hypertension, and stroke. The clotting cascade is a critical pathway that is involved in the regulation of these diseases, and F2RL1's dysfunction has been implicated in their development.

Studies have shown that F2RL1 levels are elevated in individuals with heart failure, hypertension, and stroke, and that inhibition of F2RL1 has been shown to improve these conditions. This suggests that F2RL1 may be a useful biomarker for these diseases and that its dysfunction may be a potential therapeutic target.

Conclusion

In conclusion, F2RL1 is a protein that plays a critical role in the regulation of coagulation factor II and has been shown to be a potential drug target and biomarker for several cardiovascular diseases. The inhibition of F2RL1's activity has been shown to be effective in treating thrombosis and several other cardiovascular diseases. Further research is needed to fully understand the role of F2RL1 as a drug target and biomarker, and to develop safe and effective therapies based on this protein.

Protein Name: F2R Like Trypsin Receptor 1

Functions: Receptor for trypsin and trypsin-like enzymes coupled to G proteins (PubMed:28445455). Its function is mediated through the activation of several signaling pathways including phospholipase C (PLC), intracellular calcium, mitogen-activated protein kinase (MAPK), I-kappaB kinase/NF-kappaB and Rho (PubMed:28445455). Can also be transactivated by cleaved F2R/PAR1. Involved in modulation of inflammatory responses and regulation of innate and adaptive immunity, and acts as a sensor for proteolytic enzymes generated during infection. Generally is promoting inflammation. Can signal synergistically with TLR4 and probably TLR2 in inflammatory responses and modulates TLR3 signaling. Has a protective role in establishing the endothelial barrier; the activity involves coagulation factor X. Regulates endothelial cell barrier integrity during neutrophil extravasation, probably following proteolytic cleavage by PRTN3 (PubMed:23202369). Proposed to have a bronchoprotective role in airway epithelium, but also shown to compromise the airway epithelial barrier by interrupting E-cadherin adhesion (PubMed:10086357). Involved in the regulation of vascular tone; activation results in hypotension presumably mediated by vasodilation. Associates with a subset of G proteins alpha subunits such as GNAQ, GNA11, GNA14, GNA12 and GNA13, but probably not with G(o)-alpha, G(i) subunit alpha-1 and G(i) subunit alpha-2. However, according to PubMed:21627585 can signal through G(i) subunit alpha. Believed to be a class B receptor which internalizes as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptor, for extended periods of time. Mediates inhibition of TNF-alpha stimulated JNK phosphorylation via coupling to GNAQ and GNA11; the function involves dissociation of RIPK1 and TRADD from TNFR1. Mediates phosphorylation of nuclear factor NF-kappa-B RELA subunit at 'Ser-536'; the function involves IKBKB and is predominantly independent of G proteins. Involved in cellular migration. Involved in cytoskeletal rearrangement and chemotaxis through beta-arrestin-promoted scaffolds; the function is independent of GNAQ and GNA11 and involves promotion of cofilin dephosphorylation and actin filament severing. Induces redistribution of COPS5 from the plasma membrane to the cytosol and activation of the JNK cascade is mediated by COPS5. Involved in the recruitment of leukocytes to the sites of inflammation and is the major PAR receptor capable of modulating eosinophil function such as pro-inflammatory cytokine secretion, superoxide production and degranulation. During inflammation promotes dendritic cell maturation, trafficking to the lymph nodes and subsequent T-cell activation. Involved in antimicrobial response of innate immune cells; activation enhances phagocytosis of Gram-positive and killing of Gram-negative bacteria. Acts synergistically with interferon-gamma in enhancing antiviral responses. Implicated in a number of acute and chronic inflammatory diseases such as of the joints, lungs, brain, gastrointestinal tract, periodontium, skin, and vascular systems, and in autoimmune disorders

The "F2RL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about F2RL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets